Hugel Botulinum Toxin Product 'Botulex' Approved in Ireland

[Asia Economy Reporter Lee Gwan-ju] Hugel announced on the 28th that it has obtained marketing authorization from the Ireland Health Products Regulatory Authority (HPRA) for its botulinum toxin product 'Botulax (export name Retivo)' 50Unit, indicated for glabellar wrinkles.

Including Ireland, Hugel, which has currently secured marketing authorizations in five European countries?France, Austria, the United Kingdom, and Romania?plans to complete approval and local market entry in a total of 24 countries by the end of this year. This includes 11 major countries as well as 13 Tier 2 countries such as Switzerland and Belgium.

In January of this year, Hugel received a recommendation for marketing authorization approval from the Heads of Medicines Agencies (HMA) in Europe and embarked on its first export to the European market on the 23rd.

A Hugel representative stated, “Following the receipt of the HMA’s marketing authorization recommendation, all processes toward dominating the 500 billion KRW European market?from obtaining country-specific marketing authorizations to the much-anticipated first shipment?are progressing smoothly. After entering 24 countries this year, we will complete entry into 12 Tier 3 countries next year, showcasing the strength of the Korean native company Hugel across a total of 36 European countries.”

This content was produced with the assistance of AI translation services.